Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | EVP, Chief Technical Officer | March 17, 2026 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date March 17, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 84,140 |
Reported balance
After 2026-03-17 transaction · row 1
1 source rowRow 1 · 2026-03-17 · Tax withholding · Disposed 1,693 · Balance 84,140 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2026 Filed Mar 19, 2026 20:50 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,693 | $56.05 | $94,892.65 |
DisclosureSEC source: 0001628280-26-019857 · wk-form4_1773953452.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,140 Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 00:50 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 35,680 | $0.00 Strike: $57.43 | $0.00 |
DisclosureSEC source: 0001628280-26-019012 · wk-form4_1773795035.xml · derivative · entry 3 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,680 Underlying: Common Stock · 35,680 shares Expires 2036-03-15 F3 · derivative.exercise_date: Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 00:50 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 14,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-019012 · wk-form4_1773795035.xml · nonDerivative · entry 2 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,833 F1 · price: Restricted stock units granted March 16, 2026. Price not applicable. F2 · balance_after: The Reporting Person's direct holdings have been adjusted by one share to correct a previous clerical error. Read SEC document |
| March 13, 2026 Filed Mar 18, 2026 00:50 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 9,109 | $58.51 | $532,967.59 |
DisclosureSEC source: 0001628280-26-019012 · wk-form4_1773795035.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,843 Read SEC document |
| March 11, 2026 Filed Mar 12, 2026 23:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 16,486 | $60.46 | $996,743.56 |
DisclosureSEC source: 0001628280-26-017447 · wk-form4_1773359742.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,953 F1 · price: The price in column 4 is the weighted average price. The purchase price actually received ranged from $60.39 to $60.62. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 01:49 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 2,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-012542 · wk-form4_1772156989.xml · nonDerivative · entry 3 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,439 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F5 · shares: Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 01:49 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 6,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-012542 · wk-form4_1772156989.xml · nonDerivative · entry 2 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,068 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F4 · shares: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 01:49 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 6,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-012542 · wk-form4_1772156989.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,393 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| October 31, 2025 Filed Feb 13, 2026 23:56 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 62 | $45.54 | $2,823.17 |
DisclosureSEC source: 0001628280-26-008221 · wk-form5_1771026992.xml · nonDerivative · entry 2 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,217 F2 · date: Represents the shares acquired by the reporting person on October 31, 2025, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| April 30, 2025 Filed Feb 13, 2026 23:56 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 317 | $54.14 | $17,161.43 |
DisclosureSEC source: 0001628280-26-008221 · wk-form5_1771026992.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,155 F1 · date: Represents the shares acquired by the reporting person on April 30, 2025, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 22:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 30,880 | $0.00 Strike: $71.55 | $0.00 |
DisclosureSEC source: 0001048477-25-000031 · wk-form4_1742336512.xml · derivative · entry 3 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,880 Underlying: Common Stock · 30,880 shares Expires 2035-03-16 F2 · derivative.exercise_date: Option grant vests 12/48th on March 17, 2026 and 1/48th on the 17th day of each month thereafter. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 22:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 13,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000031 · wk-form4_1742336512.xml · nonDerivative · entry 2 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,838 F1 · price: Restricted stock units granted March 17, 2025. Price not applicable. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 22:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 20,127 | $69.44 | $1,397,618.88 |
DisclosureSEC source: 0001048477-25-000031 · wk-form4_1742336512.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,528 Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 21:06 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 7,034 | $71.28 | $501,355.38 |
DisclosureSEC source: 0001048477-25-000025 · wk-form4_1741381578.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,655 F1 · price: The price in column 4 is the weighted average price. The price actually received ranged from $71.276 to $71.285. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:11 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 4,287 | $71.16 | $305,062.92 |
DisclosureSEC source: 0001048477-25-000021 · wk-form4_1741122664.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,689 Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 00:17 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000017 · wk-form4_1740701840.xml · nonDerivative · entry 3 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,976 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2025, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F5 · shares: Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 00:17 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000017 · wk-form4_1740701840.xml · nonDerivative · entry 2 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,609 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2025, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F4 · shares: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 00:17 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000017 · wk-form4_1740701840.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,949 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2025, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 19:44 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,278 | $66.37 | $350,323.56 |
DisclosureSEC source: 0001048477-24-000154 · wk-form4_1731613473.xml · nonDerivative · entry 2 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,909 F2 · price: The price in column 4 is the weighted average price. The purchase price actually received ranged from $66.37 to $66.395. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| October 31, 2024 Filed Nov 14, 2024 19:44 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 55 | $56.01 | $3,080.39 |
DisclosureSEC source: 0001048477-24-000154 · wk-form4_1731613473.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,187 F1 · date: Represents the shares acquired by the reporting person on October 31, 2024, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| May 03, 2024 Filed May 7, 2024 21:58 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 4,440 | $82.44 | $366,033.60 |
DisclosureSEC source: 0001048477-24-000077 · wk-form4_1715119099.xml · nonDerivative · entry 2 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,132 Read SEC document |
| April 30, 2024 Filed May 7, 2024 21:58 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 245 | $68.65 | $16,818.27 |
DisclosureSEC source: 0001048477-24-000077 · wk-form4_1715119099.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,572 F1 · date: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:50 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 23,630 | $0.00 Strike: $83.87 | $0.00 |
DisclosureSEC source: 0001048477-24-000046 · wk-form4_1710895840.xml · derivative · entry 3 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,630 Underlying: Common Stock · 23,630 shares Expires 2034-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2025 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:50 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 20,424 | $83.87 | $1,712,960.88 |
DisclosureSEC source: 0001048477-24-000046 · wk-form4_1710895840.xml · nonDerivative · entry 2 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,327 Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:50 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 10,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000046 · wk-form4_1710895840.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,751 F1 · price: Restricted stock units granted March 15, 2024. Price not applicable. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 6,284 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000024 · wk-form4_1709244839.xml · nonDerivative · entry 3 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,201 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F5 · shares: Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000024 · wk-form4_1709244839.xml · nonDerivative · entry 2 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,917 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F4 · shares: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 20,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000024 · wk-form4_1709244839.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,854 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:59 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-23-000051 · wk-form4_1701813536.xml · nonDerivative · entry 2 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,014 F2 · price: Restricted stock units granted on December 1, 2023. Price not applicable. Read SEC document |
| October 31, 2023 Filed Dec 5, 2023 21:59 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 133 | $69.23 | $9,207.99 |
DisclosureSEC source: 0001048477-23-000051 · wk-form4_1701813536.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,174 F1 · date: Represents the shares acquired by the reporting person on October 31, 2023, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| August 09, 2023 Filed Aug 10, 2023 20:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,360 | $93.30 | $500,109.44 |
DisclosureSEC source: 0001048477-23-000035 · wk-form4_1691700467.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,041 Read SEC document |
| May 04, 2023 Filed May 8, 2023 20:20 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 4,302 | $95.45 | $410,625.90 |
DisclosureSEC source: 0001209191-23-027934 · doc4.xml · nonDerivative · entry 2 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,401 Read SEC document |
| April 28, 2023 Filed May 8, 2023 20:20 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 239 | $66.88 | $15,984.32 |
DisclosureSEC source: 0001209191-23-027934 · doc4.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,703 F1 · date: Represents the shares acquired by the reporting person on April 28, 2023, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 20,320 | $0.00 Strike: $87.74 | $0.00 |
DisclosureSEC source: 0001567619-23-005299 · doc1.xml · derivative · entry 3 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,320 Underlying: Common Stock · 20,320 shares Expires 2033-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2024 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,856 | $87.74 | $162,845.44 |
DisclosureSEC source: 0001567619-23-005299 · doc1.xml · nonDerivative · entry 2 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,464 Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 8,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-005299 · doc1.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,320 F1 · price: Restricted stock units granted on March 15, 2023. Price not applicable. Read SEC document |
| October 31, 2022 Filed Feb 11, 2023 02:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 252 | $62.41 | $15,726.56 |
DisclosureSEC source: 0001567619-23-002422 · doc1.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,420 F1 · date: Represents shares acquired by the reporting person on October 31, 2022, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 23:52 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 6,205 | $96.56 | $599,154.80 |
DisclosureSEC source: 0001567619-22-015499 · doc1.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,168 Read SEC document |
| May 04, 2022 Filed May 7, 2022 00:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,926 | $84.65 | $332,335.90 |
DisclosureSEC source: 0001567619-22-009719 · doc1.xml · nonDerivative · entry 2 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,373 Read SEC document |
| April 29, 2022 Filed May 7, 2022 00:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 243 | $62.41 | $15,164.90 |
DisclosureSEC source: 0001567619-22-009719 · doc1.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,299 F1 · date: Represents shares acquired by the reporting person on April 29, 2022, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:30 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 26,520 | $0.00 Strike: $78.27 | $0.00 |
DisclosureSEC source: 0001567619-22-007183 · doc1.xml · derivative · entry 3 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,520 Underlying: Common Stock · 26,520 shares Expires 2032-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2023 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:30 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 920 | $78.27 | $72,008.40 |
DisclosureSEC source: 0001567619-22-007183 · doc1.xml · nonDerivative · entry 2 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,056 Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:30 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007183 · doc1.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,976 F1 · price: Restricted stock units granted on March 15, 2022. Price not applicable. Read SEC document |
| October 29, 2021 Filed Feb 12, 2022 02:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 241 | $62.41 | $15,040.09 |
DisclosureSEC source: 0001567619-22-003787 · doc1.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,936 F1 · date: Represents shares acquired by the reporting person on October 29, 2021, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| May 04, 2021 Filed May 6, 2021 00:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,986 | $78.35 | $312,303.10 |
DisclosureSEC source: 0001567619-21-009154 · doc1.xml · nonDerivative · entry 2 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,695 Read SEC document |
| April 30, 2021 Filed May 6, 2021 00:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 221 | $62.41 | $13,791.95 |
DisclosureSEC source: 0001567619-21-009154 · doc1.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,681 F1 · date: Represents shares acquired by the reporting person on April 30, 2021, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 25,650 | $0.00 Strike: $78.39 | $0.00 |
DisclosureSEC source: 0001567619-21-006557 · doc1.xml · derivative · entry 2 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,650 Underlying: Common Stock · 25,650 shares Expires 2031-03-14 F2 · date: Option grant vests 12/48th on March 15, 2022 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 10,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-006557 · doc1.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,460 F1 · price: Restricted stock units granted on March 15, 2021. Price not applicable. Read SEC document |
| May 04, 2020 Filed May 7, 2020 00:10 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 64,150 | $0.00 Strike: $90.36 | $0.00 |
DisclosureSEC source: 0001567619-20-009172 · doc1.xml · derivative · entry 2 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,150 Underlying: Common Stock · 64,150 shares Expires 2030-05-03 F2 · date: Option grant vests 12/48th on May 4, 2021 and 1/48th on the 4th day of each month thereafter. Read SEC document |
| May 04, 2020 Filed May 7, 2020 00:10 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 35,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-009172 · doc1.xml · nonDerivative · entry 1 Guyer Charles Greg · CIK 0001811096 · EVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,040 F1 · price: Restricted stock units granted on May 4, 2020. Price not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.